U.S. Markets open in 7 hrs 39 mins

Rafarma Pharmaceuticals, Inc. (RAFA)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
1.8200+0.0500 (+2.82%)
At close: 3:42PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close1.7700
Open1.7700
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range1.7500 - 1.8500
52 Week Range0.1780 - 2.9900
Volume44,075
Avg. Volume113,881
Market Cap152.638M
Beta (5Y Monthly)-1.02
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Rafarma Closes Biocogency Merger

    Nicosia, Cyprus, Oct. 19, 2020 (GLOBE NEWSWIRE) -- Rafarma Pharmaceuticals, Inc. OTC:(RAFA) is pleased to announce that it has closed the merger with BIOCOGENCY LABORATORIES. The new consolidated financials will include Slavich (http://www.slavich.ru), Slavich Trading House and related companies based in Spain, Ireland and Cyprus, with Kras Pharma (http://kraspharma.ru) and Bebig (http://en.bebig.ru/) being added in due course.The company’s Slovenian assets will be divested, per the merger agreement.Vladimir Dolgolenko, CEO of Rafarma, commented: “the new chapter has officially begun. We are very excited.”When asked about next steps, new Chairman Ilya Spurov stated: “We are already moving promptly in optimizing Rafarma’s assets to conform our U.S. strategy. My main goal is to provide all the old shareholders as well as the new ones the maximum possible market capitalization and stock liquidity through development and introduction of new products and obtaining new sales channels in the nearest possible future.”Forward-Looking Statements: This press release contains “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934. Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as “may”, “will”, “to”, “plan”, “expect”, “believe”, “anticipate”, “intend”, “could”, “would”, “estimate,” or “continue”, or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements. Forward-looking statements involve known and unknown risk, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Also, forward-looking statements represent our management’s beliefs and assumptions only as of the date hereof. Additional information regarding the factors that may cause actual results to differ materially from these forward-looking statements is available in the Company's filings with OTC Markets. Except as required by law, we assume no obligation to update these forward-looking statements publicly or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.For more information contact: RAFARMA (307) 429-2029

  • GlobeNewswire

    Rafarma Approves Issuance of Majority of Voting Shares to Board Chairman Ilya Shpurov

    Ljubljana, Slovenia, Oct. 06, 2020 (GLOBE NEWSWIRE) -- Rafarma Pharmaceuticals, Inc. OTC:(RAFA) is pleased to announce approval of Ilya Shpurov receiving the majority of Preferred B shares, conferring voting control of the company, toward the combination of its acquisition by R. & D. BIOCOGENCY LABORATORIES Group of Companies. The issuance of restricted preferred shares does not create any dilution of common shares. Vladimir Dolgolenko, CEO of Rafarma, commented: “we look forward to this new chapter in the history of the company, enhanced by the leadership of Mr. Shpurov and the enhanced value of Rafarma resulting from this transaction.”Forward-Looking Statements: This press release contains “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934. Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as “may”, “will”, “to”, “plan”, “expect”, “believe”, “anticipate”, “intend”, “could”, “would”, “estimate,” or “continue”, or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements. Forward-looking statements involve known and unknown risk, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Also, forward-looking statements represent our management’s beliefs and assumptions only as of the date hereof. Additional information regarding the factors that may cause actual results to differ materially from these forward-looking statements is available in the Company's filings with OTC Markets. Except as required by law, we assume no obligation to update these forward-looking statements publicly or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.For more information contact: RAFARMA (307) 429-2029

  • Rafarma Adds Prestigious New Board Chairman Ilia Shpurov
    GlobeNewswire

    Rafarma Adds Prestigious New Board Chairman Ilia Shpurov

    Rafarma Pharmaceuticals, Inc Mr. ShpurovLjubljana, Slovenia, Sept. 18, 2020 (GLOBE NEWSWIRE) -- Rafarma Pharmaceuticals, Inc. OTC:(RAFA) is pleased to announce the appointment of Ilia Shpurov as Chairman of the Board. Mr. Shpurov has a long history of technological developments, patents and entrepreneurial achievements in biotech. Most recently Mr. Shpurov purchased Kraspharma (http://kraspharma.ru) in 2008 and has built it into one of the top pharmaceutical companies in Russia. Mr. Shpurov also created the Pereslavsky Group technology park in 2004. It is now the largest technology park in Russia in terms of residents and size (4 square kilometers of land and 560,000 meters in building space). Mr. Shpurov is also Vice President of the International Congress of Industrialists and Entrepreneurs (http://www.ic-ie.com) . Mr. Shpurov brings unique experience to the board of directors and is a well-known businessman throughout Europe. His expertise in pharmaceutical growth will power Rafarma toward its goals of worldwide growth and profitability.Vladimir Dolgolenko CEO of Rafarma stated “we are very excited Mr. Shpurov has joined the board. His expertise, knowledge, reputation and resources will prove invaluable to the company in the coming months and years. We are extremely excited for the opportunities he brings to the company moving forward.”Forward-Looking Statements: This press release contains “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934. Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as “may”, “will”, “to”, “plan”, “expect”, “believe”, “anticipate”, “intend”, “could”, “would”, “estimate,” or “continue”, or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements. Forward-looking statements involve known and unknown risk, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Also, forward-looking statements represent our management’s beliefs and assumptions only as of the date hereof. Additional information regarding the factors that may cause actual results to differ materially from these forward-looking statements is available in the Company's filings with OTC Markets. Except as required by law, we assume no obligation to update these forward-looking statements publicly or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.For more information contact: RAFARMA (307) 429-2029Attachment * Rafarma Pharmaceuticals, Inc